Approval · Notice of Compliance 24211 · 2020
TRULICITY: Notice of Compliance 24211
Issued September 11, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24211
- Date
- September 11, 2020
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication and product monograph updte: trulicity is indicated as an adjunct to diet, exercise and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes melitus who have multiple cardiovascular risk factors or established cardiovascular disease
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRULICITY | Not yet assigned | — |
Medicinal ingredients
- DULAGLUTIDE 0.75 MG per 0.5ML
- DULAGLUTIDE 1.5 MG per 0.5ML
- DULAGLUTIDE 0.75 MG per PEN
- DULAGLUTIDE 1.5 MG per PEN